DEBUG: PAGE=domain, TITLE=Healthcare & Pharmaceuticals,ID=1436,TEMPLATE=bpomarket
toggle expanded view

Search within: Healthcare & Pharmaceuticals:

Access our analyst expertise:

Only NelsonHall clients who are logged in have access to our analysts and advisors for their expert advice and opinion.

To find out more about how NelsonHall's analysts and sourcing advisors can assist you with your strategy and engagements, please contact our sales department here.

Subscribe to blogs & alerts:

manage email alerts using the form below, in order to be notified via email whenever we publish new content:

Genpact Announces Q1 2022 Revenues Up 12.9% (Up 14% in CC) to $1,068.4m

Financial Results

by

published on May 06, 2022

Genpact has announced results for Q1 2022:

  • Revenues were $1,068.4m, 12.9%y/y,  14% in CC
  • EBIT was $133.9m, an EBIT margin of 12.5%, down 1.0 bps y/y
  • Adjusted EBIT was $160.-m, an adjusted EBIT margin of 15.0%, down 22.2bps y/y.

Q1 2022 revenue (and y/y growth) by client type was:

  • Global Clients: $973.3m (+14.1%, +15% in CC)
  • GE: $95.2m (+2.3%).

Q1 2022 revenue (and y/y growth) by sector was:

  • BFSI: $276.2m (+14.0%)
  • Consumer Goods $404.2m (+18.9%)
  • Manufacturing and Services: $394.9m (+10.7%)
  • Other: ($6.8) (-200.7%).

 Key clients at the end of Q1 2022: the number of clients in different bands of annual revenue contribution (and in the prior year period) is:

  • >$25m:  29 (23)
  • $5m-$15m: 90 (85)
  • $15m-$25m: 119 (108)

As at end March 2021, Genpact has ~113,500 employees worldwide, up 16.9% from ~97.1k at end March 2021.

TTM attrition rate, measured from the first day of employment, was 33%, up from 25% previous year.

Full year revenue guidance is $4.325-$4.4bn, an increase of 9.0-11.0% in CC.

VendorGenpact
Initial currency type (specify local currency used)US$
Period Ending2022-03-31
Growth12.9
Revenues ((m) in local currency1068.4
Revenues (in $m at that date)1068.4

Rate this article

rate this
No votes
close